Days post-infection | Population 10 (LC50 = 0.415 µg/mL)a | Population 14 (LC50 = 0.144 µg/mL)b | Population 16 (LC50 = 0.481 µg/mL)c | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Control | Treatment | Efficacy | p value | CV | Control | Treatment | Efficacy | p value | CV | Control | Treatment | Efficacy | p value | CV | |
0 (day of infection) | 95.1a | 95.6a | 0.9515 | 11.47 | 19.7a | 19.9a | 0.8923 | 4.9 | 33.7a | 33.43a | 0.9613 | 9.55 | |||
+3 | 99.0a | 0.0b | 100 | < 0.0001 | 16.45 | 22.7a | 0.0b | 100 | < 0.0001 | 13.38 | 27.0a | 0.0b | 100 | < 0.0001 | 30.37 |
+7 | 102.2a | 0.0b | 100 | < 0.0001 | 18.11 | 24.6a | 0.0b | 100 | < 0.0001 | 13.21 | 26.9a | 0.0b | 100 | < 0.0001 | 22.89 |
+14 | 89.8a | 0.0b | 100 | < 0.0001 | 16.42 | 29.4a | 0.0b | 100 | < 0.0001 | 16.48 | 25.3a | 0.0b | 100 | < 0.0001 | 13.33 |
+21 | 90.3a | 0.0b | 100 | < 0.0001 | 19.42 | 30.2a | 0.0b | 100 | < 0.0001 | 13.4 | 31.8a | 0.0b | 100 | < 0.0001 | 4.23 |
+28 | 93.4a | 0.0b | 100 | < 0.0001 | 16.93 | 37.0a | 0.0b | 100 | < 0.0001 | 19.97 | 26.8a | 0.0b | 100 | < 0.0001 | 6.51 |
+35 | 78.7a | 0.0b | 100 | < 0.0001 | 23.66 | 41.4a | 0.1b | 99.8 | < 0.0001 | 19.29 | 31.7a | 0.0b | 100 | < 0.0001 | 8.63 |
+42 | 54.9a | 2.5b | 95.5 | < 0.0001 | 28.1 | 41.0a | 4.1b | 90.1 | < 0.0001 | 35.24 | 27.6a | 1.4b | 94.9 | < 0.0001 | 22.01 |
+49 | 45.1a | 7.0b | 84.6 | < 0.0001 | 31.39 | 41.5a | 7.5b | 82.1 | 0.0001 | 32.92 | 24.8a | 4.80b | 80.5 | 0.0020 | 47.49 |
+56 | 38.3a | 24.5a | 36.4 | 0.1597 | 26.08 | 39.4a | 20.0b | 49.7 | 0.0180 | 28.51 | 30.9a | 12.60b | 58.9 | 0.0024 | 35.27 |
Therapeutic efficacy (up to day +21) | 100 | 100 | 100 | ||||||||||||
Persistent efficacy (day +28 to day +42) | 98.9 | 96.5 | 98.2 |